TY - JOUR
AR - SCR-2021-9-113
TI - A New Device for Managing Refractory Epistaxis in ICU Patients with COVID-19
AU - Olivier, Choussy
AU - Nicolas, Viault
AU - Wahib, Ghanem
AU - Antoine, Dubray Vautrin
AU - Christian, Lamer
JO - Surgical Case Reports
PY - 2021
DA - Thu 30, Sep 2021
SN - 2613-5965
DO - http://dx.doi.org/10.31487/j.SCR.2021.09.13
UR - https://www.sciencerepository.org/a-new-device-for-managing_SCR-2021-9-113 
KW - Epistaxis treatment, COVID-19, recurrent epistaxis
AB - Epistaxis is a common and a well-known symptom. Nasal packing is an effective treatment in most cases [1]. The COVID-19 disease treatment includes conventional or high flow nasal oxygen therapy and systemic anticoagulation [2]. Patients in intensive care unit may require therapeutic anticoagulation for venous thromboembolism, hyperinflammatory status, extracorporeal membrane oxygenation (ECMO) and multiple other pathologies. The use of therapeutic anticoagulation increases risk of nose bleeding, and its management may be challenging. CAVI-T (Figures 1 & 2) is a new asymmetrical low-pressure balloon that have shown promising results to control epistaxis in emergency. We report herein the management of severe epistaxis in two COVID-19 patients admitted to ICU for severe respiratory failure.